1st Department of Medicine Department of Hematology 1st Faculty of Medicine Charles University and General Hospital Prague Czech Republic

Centre Hospitalo Universitaire Université de Toulouse UPS Toulouse

Dana Farber Cancer Institute Boston MA

Department of Haematology Lille University Hospital Lille

Department of Hematology Japanese Red Cross Medical Center Tokyo

Department of Hematology University Hospital of Nantes Nantes

IT M Statistics for Sanofi Neuilly sur Seine

IVIdata for Sanofi Levallois Perret

Sanofi Research and Development Cambridge MA

Sanofi Research and Development Vitry Sur Seine

UCSF Medical Center San Francisco CA

Zobrazit více v PubMed

Bisht K, Walker B, Kumar SK, et al. . Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol. 2021;14(12):1099-1114. PubMed

Hanamura I. Gain/amplification of chromosome arm 1q21 in multiple myeloma. Cancers (Basel). 2021;13(2):256. PubMed PMC

Hanamura I, Stewart JP, Huang Y, et al. . Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724-1732. PubMed PMC

Attal M, Richardson PG, Rajkumar SV, et al. . Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107. PubMed

Moreau P, Dimopoulos MA, Mikhael J, et al. . Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. PubMed

Harrison SJ, Perrot A, Alegre A, et al. . Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120-131. PubMed PMC

Spicka I, Moreau P, Martin TG, et al. . Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. J Clin Oncol. 2021;39(s15):8042. PubMed PMC

Rajkumar SV, Harousseau JL, Durie B, et al. . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695. PubMed PMC

D'Agostino M, Ruggeri M, Aquino S, et al. . Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the Forte trial. Blood. 2020;136(Suppl 1):38-40.

Mina R, Zamagni E, Fazio F, et al. . Efficacy of carfilzomib-based induction/consolidation with or without autologous transplant and lenalidomide or carfilzomib-lenalidomide maintenance in high-risk patients in the Forte trial. HemaSphere. 2021;5(S2):46-47 (abstract S182).

Mohan M, Weinhold N, Schinke C, et al. . Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2020;189(1):67-71. PubMed

Hu X, Wu CH, Cowan JM, Comenzo RL, Varga C. Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. Ann Hematol. 2022;101(2):369-378. PubMed

Nijhof IS, Casneuf T, van Velzen J, et al. . CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959-970. PubMed

van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13-29. PubMed

Zhu C, Song Z, Wang A, et al. . Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020;11:1771. PubMed PMC